Brief Description
Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.
The company was co-founded by Greg Timblin and Josh Farahzad. CEO Timblin earned his Ph.D. in Molecular & Cell Biology from UC Berkeley in 2014, in the labs of Professors Mark Schlissel and Robert Tjian. He also served as a postdoctoral fellow in Professor Kaoru Saijo’s lab at UC Berkeley, and then in Professor Val Weaver’s lab at UCSF.
Inventors
Kaoru Saijo, Greg Timblin
Company Founders
Greg Timblin (UC Berkeley, B.A. ’08, Biology & Chemistry; Ph.D. ’14, Molecular Biology)
Timeline
- 2023. Company founded; tenant at Bakar Labs, in the UC Berkeley Bakar BioEnginuity Hub